Technical Analysis for PROK - ProKidney Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Boomer Buy Setup | Bullish Swing Setup | 6.99% | |
| Calm After Storm | Range Contraction | 6.99% | |
| Upper Bollinger Band Walk | Strength | 6.99% | |
| Inside Day | Range Contraction | 6.99% | |
| Wide Bands | Range Expansion | 6.99% | |
| Overbought Stochastic | Strength | 6.99% |
| Alert | Time |
|---|---|
| Rose Above Upper Bollinger Band | 1 day ago |
| Up 5% | 2 days ago |
| Boomer Buy Entry | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
| Outside Day | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/03/2024
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.51 |
| 52 Week Low | 1.12 |
| Average Volume | 823,442 |
| 200-Day Moving Average | 3.28 |
| 50-Day Moving Average | 2.09 |
| 20-Day Moving Average | 2.76 |
| 10-Day Moving Average | 3.14 |
| Average True Range | 0.39 |
| RSI (14) | 72.90 |
| ADX | 37.43 |
| +DI | 39.36 |
| -DI | 7.11 |
| Chandelier Exit (Long, 3 ATRs) | 3.15 |
| Chandelier Exit (Short, 3 ATRs) | 3.13 |
| Upper Bollinger Bands | 4.08 |
| Lower Bollinger Band | 1.43 |
| Percent B (%b) | 0.99 |
| BandWidth | 96.27 |
| MACD Line | 0.49 |
| MACD Signal Line | 0.33 |
| MACD Histogram | 0.1595 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.60 | ||||
| Resistance 3 (R3) | 4.55 | 4.31 | 4.51 | ||
| Resistance 2 (R2) | 4.31 | 4.17 | 4.33 | 4.48 | |
| Resistance 1 (R1) | 4.18 | 4.08 | 4.24 | 4.24 | 4.45 |
| Pivot Point | 3.94 | 3.94 | 3.97 | 3.97 | 3.94 |
| Support 1 (S1) | 3.82 | 3.80 | 3.88 | 3.87 | 3.66 |
| Support 2 (S2) | 3.58 | 3.71 | 3.60 | 3.63 | |
| Support 3 (S3) | 3.45 | 3.58 | 3.60 | ||
| Support 4 (S4) | 3.51 |
